↓ Skip to main content

Developing and financing neglected disease vaccines in our new era of “blue marble health” and the anthropocene epoch

Overview of attention for article published in Vaccine, September 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
1 news outlet
twitter
2 tweeters

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
21 Mendeley
Title
Developing and financing neglected disease vaccines in our new era of “blue marble health” and the anthropocene epoch
Published in
Vaccine, September 2017
DOI 10.1016/j.vaccine.2017.02.002
Pubmed ID
Authors

Peter J. Hotez

Abstract

New findings of widespread neglected diseases among the poor living in wealthy group of 20 (G20) economies and the concept of "blue marble health" offer innovative mechanisms for financing urgently new vaccines, especially for vector-borne neglected tropical diseases (NTDs). This approach could complement or parallel a recently suggested global vaccine development fund for pandemic threats.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 33%
Student > Ph. D. Student 4 19%
Student > Master 4 19%
Unspecified 3 14%
Other 1 5%
Other 2 10%
Readers by discipline Count As %
Unspecified 5 24%
Agricultural and Biological Sciences 3 14%
Medicine and Dentistry 3 14%
Immunology and Microbiology 3 14%
Social Sciences 2 10%
Other 5 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 March 2017.
All research outputs
#1,236,659
of 12,269,726 outputs
Outputs from Vaccine
#943
of 10,556 outputs
Outputs of similar age
#43,771
of 258,112 outputs
Outputs of similar age from Vaccine
#39
of 202 outputs
Altmetric has tracked 12,269,726 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,556 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 258,112 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 202 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.